By Sabela Ojea

Phathom Pharmaceuticals said the U.S. Food and Drug Administration approved Voquezna to treat a type of esophagus inflammation.

The commercial-stage biopharmaceutical company said the FDA approved the novel potassium-competitive acid blocker as a new treatment for adults dealing with erosive esophagitis.

The approval is based on positive results from the phase 3 Phalcon-EE study, which enrolled over 1,000 patients in the U.S. and Europe.

Voqezna is expected to be available in the U.S. in December, the company said.

The FDA approval entitles Phathom Pharmaceuticals to receive a $175 million payment, which will fund the commercial launch.

Write to Sabela Ojea at sabela.ojea@wsj.com

(END) Dow Jones Newswires

November 01, 2023 17:35 ET (21:35 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Phathom Pharmaceuticals (NASDAQ:PHAT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos Phathom Pharmaceuticals.
Phathom Pharmaceuticals (NASDAQ:PHAT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos Phathom Pharmaceuticals.